KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Johnny Mahlangu, Ana Boban, Maria Bruzelius, Giancarlo Castaman, Kingsley Hampton, Paul Knoebl, Aurélien Lebreton, Silvia Linari, Francisco-José López-Jaime, Camila Martins Mazini Tavares, Mohamed Salim Nekkal, Keiji Nogami, Amalie Rhode Høgh Nielsen, Amy Shapiro, Roseline d'Oiron

Blood Adv 10(6) 1854-1863

PMID41499759
PMCIDPMC12993885
DOI10.1182/bloodadvances.2025018264
发表日期2026-01-07
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 1.:非 KM 图;Figure 2.:图注未提示 KM 曲线。
摘要

摘要

Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for once-daily subcutaneous prophylactic treatment for people with hemophilia A or B with and without inhibitors. Results from the phase 3 explorer7 study confirmed superiority of concizumab prophylaxis over no prophylaxis in reducing the annualized bleeding rate (ABR) in people with hemophilia A or B with inhibitors (HAwI/HBwI). Male patients aged ≥12 years were randomized 1:2 to no prophylaxis (group 1) or concizumab prophylaxis (group 2), or nonrandomly allocated to concizumab prophylaxis (groups 3 and 4). After ≥24 weeks of treatment, patients in group 1 could switch to concizumab prophylaxis. At the 56-week cutoff (defined as when all patients in groups 2-4 had completed the visit at 56 weeks or permanently discontinued treatment), bleed-related efficacy, pharmacokinetics and pharmacodynamics, and safety were assessed. Of the 133 patients enrolled (HAwI, n = 80; HBwI, n = 53), 114 received concizumab prophylaxis (groups 2-4) and 19 were randomized to no prophylaxis (group 1). After ≥24 weeks, 13 patients from group 1 switched to concizumab. Median ABR for treated spontaneous and traumatic bleeding episodes in patients receiving concizumab was 0.8 (interquartile range [IQR], 0.0-3.2) at the 56-week cutoff, consistent with the low bleeding rates (median ABR, 0.0; IQR, 0.0-3.3) at the 32-week cutoff. Concizumab and free-TFPI concentration remained stable over time. No new safety concerns were reported. Longer-term (≥1 year) efficacy and safety results of concizumab prophylaxis for HAwI/HBwI were consistent with the 32-week cutoff results in explorer7. This trial was registered at www.clinicaltrials.gov as #NCT04083781.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.Explorer7 patient disposition at the 56-week cutoff. Of 133 patients enrolled, 127 received concizumab prophylaxis, and 104 completed the study at the 56-week cutoff. a The 32-week cutoff was defined as when patients have completed at least 24 weeks (group 1) or 32 weeks of participation (group 2). b Randomized/allocated patients who did not discontinue concizumab treatment before the 56-week cutoff. OnD, on-demand; PPX, prophylaxis.
非 KM Figure
Figure 2.PK/PD results in explorer7 at the 56-week cutoff. Error bars represent ± standard error of the geometric mean. Number of patients shown at the bottom of the figure reflects the number of patients contributing with nonzero values. PPX, prophylaxis. (A) Geometric mean concizumab plasma concentration over time. (B) Geometric mean free-TFPI concentration over time. (C) Geometric mean pre-dose thrombin peak over time.
非 KM Figure